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Summary
  Malignant neoplasm arising in chronic, non-healing wounds has been known 
since ages and it was named Marjolin’s ulcer about one hundred years ago. This 
scar malignancy arises in burned, constantly injured or chronically inﬂ amed skin. 
Such pathologies as osteomyelitis, decubitus ulcers, chronic ﬁ stulas, frost bite, 
chronic venous failure, vaccination sites, skin graft donor sites and chronically 
traumatized skin are numbered among the etiological factors. Despite these nu-
merous risk factors this oncological syndrome is rarely diagnosed and common-
ly mistaken, thus it may often be overlooked. Marjolin’s ulcer may be deﬁ ned 
by many pathological types of neoplasms. Squamous cell carcinoma (SCC) is 
the most commonly identiﬁ ed histological type followed by basal cell carcinoma 
(BCC), malignant melanoma, sarcomas (ﬁ brosarcoma, liposarcoma, dermatoﬁ -
brosarcoma protuberans, mesenchymal tumor), mixed tumors: SCC-BCC, SCC-
melanoma and others. There is an agreement over the prevention methods with 
skin grafting of burned areas and excision with simultaneous grafting of ulcer-
ations appearing in non-healing wounds. To date, there has not been a consen-
sus reached over the treatment protocol. Wide surgical excision seems to be the 
most preferred method. Inoperable cases and recurrences may be treated with 
radiotherapy alone or combined with chemotherapy.
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BACKGROUND
Marjolin’s ulcer is an often overlooked pathol-
ogy arising in burned, constantly injured or 
chronically inﬂ amed skin. Cancers developing in 
scar tissues were ofﬁ cially named Marjolin’s ul-
cer in 1903 by Da Costa [1]. In 1828 Jean Louis 
Marjolin, French physician, described an ulcer-
ation in scar tissue, however without stating if it 
is capable of malignant transformation [2]. At 
the same time Dypuytren presented a case where 
a patient, several years earlier burned with sul-
furic acid, underwent amputation because of a 
cancer that developed in the scar tissue site [3]. 
Literature contains even earlier reports on scar 
neoplasms. Earliest from about 100 A.C. by Celsus 
on cancers developing in burn scars [4].
ETIOPATHOLOGY AND HISTOLOGY
For many years the term Marjolin’s ulcer was 
used as a synonym of burn scar neoplasm [5]. 
Nowadays the etiology of scar neoplasms has 
widened. There are several pathologies of skin 
known to be potential sites of Marjolin’s ulcer de-
velopment, among them: osteomyelitis [6], decu-
bitus ulcers [6,7], chronically traumatized skin 
[6], chronic ﬁ stulas [8], frost bite [9], chronic 
venous failure [10,11], vaccination sites [12] and 
skin graft donor sites [13].
There are various theories concerning the mech-
anism of scar malignancy development. Scar tis-
sue is generally less resistant to injuries and it 
heals with difﬁ culty, especially in sites such as the 
joint area. It is postulated that cells forming the 
scar tissues release toxins by autolysis and heter-
olysis. The healing phase is therefore prolonged 
and groups of rapidly dividing cells susceptible 
to mutagens form [14]. Blood vessels and lym-
phatics regenerate poorly. Scar tissue than be-
comes an immunologically crippled site where 
tumor cells can escape the immunological elim-
ination processes [15].
In most cases, histologically, Marjolin’s ulcer 
is a squamos cell carcinoma (SCC) – 73%, fol-
lowed by basal cell carcinoma (BCC) – 10%. 
Malignant melanoma, sarcomas (among them: 
ﬁ brosarcoma, liposarcoma, dermatoﬁ brosarco-
ma, protuberans, mesenchymal tumor), mixed 
tumors: SCC-BCC, SCC-melanoma are less fre-
quent  (Table 1) [6,7,11,13,16,17]. The incidence 
of SCC and BCC in patients with Marjolin’s ul-
cer is inversely proportional to their occurrence 
in the general population. Marjolin’s ulcer de-
velops into BCC when the injury leading to scar 
formation is superﬁ cial and spares the skin ad-
nexa which are necessary to regenerate the epi-
dermis within which the basal cells lay.
DIAGNOSIS, PREVENTION AND TREATMENT
There is a lag period between the development 
of Marjolin’s ulcer in a scar tissue and the time 
of injury. It has been observed that the laten-
cy is inversely proportional to the patients’ age. 
Malignant transformation is delayed in young-
er injury victims. The older the patient at the 
time of injury the shorter the lag period. The 
average latency period is 36 years and the aver-
age patients’ age at the time of diagnosis is 52. 
Male/female ratio is 2:1. Incidence in women 
is greater only in cases of malignant melanoma 
[6,7,10,13,16,17].
Lower extremities are the most commonly affect-
ed sites – 36% of the cases in our study. Next is 
the head region (with face, scalp and neck), fol-
lowed by the upper extremities and the trunk 
(Table 1.) [6,7,10,13,16,17].
Marjolin’s ulcer is commonly mistaken for an 
infected ulceration occurring at the scar tissue 
sites. Changes such as the appearance of ﬂ at, 
non-healing ulcers enlarging in circumference 
with elevated and indurated borders, foul-smell-
ing, painful with exudate and bloody drainage 
suggest a malignant transformation. Quite of-
ten, additional X-ray may show bone destruction. 
Surgical biopsy performed in multiple sites is rec-
ommended to conﬁ rm the neoplasmatic conver-
sion [10,18,20].
Most researchers agree that the best prevention 
of these scar malignancies is primary skin grafting 
of the burn sites. Chronic ulcerations appearing 
in non- healing wounds should be excised and 
also skin grafted [17,18,19,20]. Unfortunately di-
agnosis is often delayed. As a result approximate-
ly 30% of the cases have enlarged lymph nodes 
with possible metastasis [6,18,20]. 449 cases re-
viewed in this article conﬁ rmed the highly met-
astatic potential of Marjolin’s ulcer. Available 
data showed lymph node invasion in 19% of the 
cases and 13% had distant metastases (Table 1) 
[6,7,11,13,16,17]. Compared to the general popu-
lation, malignant melanoma conﬁ rmed high met-
astatic potential among skin malignancies.
Treatment of Marjolin’s ulcer should be multi-
disciplinary. Although there has not yet been a 
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consensus reached over the management proto-
col, we agree with most of the researchers that 
surgery is the primary treatment. First of all, ex-
cision should be performed with cautery (which 
is believed to be safer as it may prevent metasta-
sis by preventing tumor cells from being washed 
into the blood and lymph systems) with the ad-
dition of a small margin, for the skin, performed 
with a surgical scalpel for better healing [18,20]. 
Excision of ulcers should include a 3–4cm mar-
gin of normal skin with muscle and fascia due to 
the high metastatic potential and recurrence ten-
dency [6,18,20]. Defects are usually skin grafted 
either with free ﬂ aps or split-thickness skin grafts 
(STSG) [18,20]. If there is a clinically palpable 
lymphadenopathy, lymph node dissection is rec-
ommended [5,6,17,18,20] with an exception for 
malignant melanoma, where the sentinel lymph 
node biopsy should be performed regardless of 
the presence of enlarged lymph nodes. In cases 
where surgery is impossible or inadequate, radi-
otherapy alone or combined with chemotherapy 
should be performed [6,16,17]. Chemotherapy 
is usually based on 5-Fluorouracil with a combi-
nation of Cisplatin and Methotrexate [17].
CONCLUSIONS
Review of literature suggests that Marjolin’s ul-
cer is an infrequent lesion. In general this disor-
der is rarely diagnosed although its etiology is well 
known. Unfortunately the diagnosis and treatment 
are usually delayed. Therefore burns, especially full 
thickness burns, should be skin grafted. Non-heal-
ing wounds, ﬁ stulas and chronically inﬂ amed skin 
must be properly treated. Any suspicious lesions 
that arise within affected areas should call for mul-
tiple biopsies as a gold standard. Patients suffering 
from burns or other skin pathologies leading to 
the formation of scar tissue or ﬁ stulas must have 
greater vigilance and receive medical help imme-
diately when their fragile scars ulcerate.
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Incidence of Marjolin’s ulcer Number(%)
Lymph node invasion number 
(%)
Distant metastases number
(%)
Histopathology:
 Squamous cell carcinoma
 Basal cell carcinoma
 Malignant melanoma
 Sarcoma
 Other
 Squamous-basal
 Squamous -melanoma
Total:
 329 (73)
 48 (10)
 24 (6)
 21 (5)
 16 (4)
 6 (1)
 5 (1)
 449 (100)
 81 (24)
 0 (0)
 7 (29)
 unavailable data
 unavailable data
 unavailable data
 unavailable data
 87 (19)
 55 (17)
 0 (0)
 5 (21)
 unavailable data
 unavailable data
 unavailable data
 unavailable data
 60 (13)
Location:
 Lower extremities
 Upper extremities
 Head
 Trunk
Total:
 162 (36)
 130 (29)
 81 (18)
 76 (17)
 449 (100)
Table 1. Pathology and localization of Marjolin’s ulcer [6,7,11,13,16,17].
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